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Abstract
Purpose: Over the past three decades our centre has adopted a policy of conservative surgery followed by adjuvant radical-
dose radiotherapy for medium- and high-grade soft tissue sarcomas. For all cases of local recurrence following this treatment
we aimed to define the spatial relationship between sites of recurrence and the positions of the phase 1 and 2 radiotherapy
volumes.
Patients: We identified 25 cases of local recurrence recorded on our soft tissue sarcoma database between 1986 and 1999
inclusive. We excluded patients with macroscopic residual disease following surgery. Most patients were treated with a phase
I volume corresponding to the entire muscle compartment (50 Gy in 25 fractions over 5 weeks) and a phase II volume corre-
sponding to the tumour bed (10 Gy in five fractions). Six of the patients were treated according to a hyperfractionated
regimen.
Methods: For each case we reviewed the diagnostic imaging, planning radiographs and prescription sheets. We audited
whether treatment had been given according to protocol and defined whether recurrence had arisen in the phase 1 volume,
phase 2 volume or ‘out of field’.
Results: Four (16%) patients recurred within the phase I volume, 17 (68%) recurred within the phase II volume and four
(16%) outside the irradiated volume including one marginal recurrence. In six patients there had been deviation from our
radiotherapy protocol (usually unavoidable) including all three true out of field recurrences.
Discussion: The majority of recurrences occur in the phase 2 volume. Prospective multi-centre data collection and, ideally,
a prospective randomised trial are required to formulate an improved treatment policy with respect to radiotherapy margins
and dose.
Key words: sarcoma, post-operative radiotherapy, recurrence, conservative surgery
Introduction
The recommended treatment of resectable high-grade
soft tissue sarcoma is conservative, organ-preserving
surgery  followed  by  adjuvant  radical  radiotherapy.
Combined  modality  treatment  of  this  nature  can
achieve 5-year local control rates of 85–90%1–7 and 5-
year overall survival rates in excess of 70%.1–3,5,7,8 In
terms  of  local  control  and  survival  this  compares
favourably with the results achieved by radical surgery
or amputation.5,9,10 In addition to a local failure rate
of up to 20% at 5 years, local recurrences later than
this have been documented.2 Approximately 60% of
recurrences are salvageable with further surgery but
this may involve amputation.2–4
In delivering postoperative radiotherapy we aim to
improve functional outcome by reducing the extent
of  surgical  resection  required  to  achieve  cure.
However, radiotherapy morbidity can also impact on
function  and  there  is  evidence  that  the  risk  of
complications increases with both dose7,8,11 and field
size.11  Between  sarcoma  units  practice  varies
considerably  with  respect  to  the  size  of  radiation
portal  employed relative to the tumour bed; some
centres, including ours, irradiate the entire muscular
compartment  whilst  others  utilise  a  much  smaller
volume, treating the tumour bed with a margin of a
few centimetres only by means of brachytherapy.12
Over the last two decades our unit has adopted a
treatment policy of conservative surgery and adjuvant
radiotherapy for all high and medium-grade tumours.
The majority of patients are treated in accordance
with a strict radiotherapy protocol.13 Our sarcoma
database was used to identify 25 cases of local recur-
rence dating back to 1986.  Disease and treatment
details relating to each case were analysed to identify
the exact spatial relationship between site of recur-
rence and the irradiated volume.84 Cleator et al.
Patients and methods
Patient and tumour characteristics (Tables 1 and 2)
Since 1973 all new patients seen in our multidiscipli-
nary sarcoma unit have been prospectively recorded
on a database. This was used to identify patients who
had demonstrated local relapse following conserva-
tive surgery and adjuvant radiotherapy. Planning and
diagnostic  radiographs  were  available  for  cases
recorded since 1986  and hence our analysis  dates
back to this time. Patients with residual macroscopic
disease following surgery or with metastatic disease
(including  nodal  disease)  at  original  presentation
were  excluded.  Low-grade  sarcomas  were  treated
with postoperative radiotherapy only if they demon-
strated multiple local recurrences or were associated
with  unresectable residual disease.  The  study  was
closed in 1999 resulting in a median follow-up time
from completion of radiotherapy to time of writing of
58 months (range 16–150 months). Patients treated
with preoperative radiotherapy have not been ana-
lysed.  The  patient  and  tumour  characteristics  are
summarised in Table 1. All histology was reviewed in
our centre by the same pathologist. The median age
at presentation was 56 (range 17–86). Tumours aris-
ing  in  the  limb  and  girdle  comprised  88%,  the
remainder arising within the trunk. The percentage of
tumours which were grade 1, 2 and 3 were 8, 32 and
60%,  respectively.  T1  tumours comprised 36%  of
patients  and  64%  were  T2.  Patients  were  staged
according to the 1997 International Union Against
Cancer (UICC) staging system.14 Surgical margins
were positive or ‘probably positive’ in nine patients
(38%).  In  nine  patients  tumours  were  recurrent,
having been previously treated by surgery alone. Four
patients had metastatic disease at time of local recur-
rence.  The  total  number  of  patients  of  this  type
treated over this period was 239, resulting in a local
recurrence rate  of  10.5%.  The  histological  break-
down of the 239 patients is displayed in Table 2.
Treatment details (Table 3)
All patients were reviewed prior to treatment by the
multidisciplinary team consisting of surgeon, radiol-
ogist, medical and clinical oncologist. Some patients
underwent surgery in another institution and were
referred for adjuvant treatment. When previous sur-
gery was considered sub-optimal and where techni-
cally  feasible,  wide  re-excision  was  performed.  A
comprehensive work-up included physical examina-
tion, preoperative MRI or CT scan of the region of
disease and a CT scan of the lungs. All patients were
treated under the supervision of a single radiothera-
pist.
Our standard radiotherapy treatment policy is to
include the entire length of the involved muscle or
muscle groups in the phase 1 planning target volume
(PTV). Thereafter the PTV is reduced as a phase 2
consisting of the original tumour extent with a 2-cm
margin. Where beneficial, treatment is CT-planned
and wedges or remote tissue compensators are used
to optimise the dose distribution. Customised casts
Table 1. Recurrences, patient and tumour characteristics
Factor
Number 
of 
patients Percentage
Age at diagnosis (years):
<30 2 8
30–60 14 56
>60 9 36
Median 56
Gender:
Male 13 52
Female 12 48
Site:
Limb and girdle 22 88
Trunk 3 12
Time to relapse (months):
Range  3–86
Median 21
Histological type:
Liposarcoma 3
Leiomyosarcoma 8
Malignant fibrous 
histiocytoma
6
Synovial sarcoma 4
Dermatosarcoma 
protruberans
1
Fibrosarcoma 1
Unclassified high-grade 
sarcoma
2
Grade:
1 2 8
2 8 32
3 15 60
Stage:
T1 (5 cm or less) 9 36
T2 ( more than 5 cm) 16 64
Margins:
Positive 9 36
Negative 16 64
Table 2. Histological profile of total patients treated
Histological types
Number (%) 
(n = 239)
Number of 
recurrences 
(%)
Leiomyosarcoma 55 (23) 8 (14.5)
Malignant fibrous 
histiocytoma
52 (22) 6 (11.5)
Liposarcoma 37 (15) 3 (8)
Synovial sarcoma 33 (14) 4 (12)
MPNSTa 13 (5) 0
Ewings 6 (3) 0
Fibrosarcoma 3 (1) 1 (33)
Dermatofibrosarcoma 
protruberans
2 (1) 1 (50)
Others/unspecifiedb 38 (16) 2
aMalignant peripheral nerve sheath tumour.
bClear cell sarcoma, chondrosarcoma, haemangiopericy-
toma, adult rhabdomyosarcoma, fibromatosis (two cases), 
epithelioid saracoma, angiosarcoma.Pattern of local recurrence 85
are  used  to  immobilise  extremities  and  fields  are
shaped with lead blocks or cut-outs. Irradiation of the
entire circumference of a limb is avoided, with care
being taken to spare a corridor of skin and subcuta-
neous tissue. In both phases joints are spared as much
as possible. When advantageous, three-dimensional
planning and conformal radiotherapy with use of the
multileaf collimator are utilised.15
Most patients were treated with high energy 5- or
6-MV photons alone, usually with parallel opposed
beams which were sometimes angled. The phase 1
volume was treated to a dose of 50 Gy (to 100%) in
25  daily  fractions  over  5  weeks  and  the  phase  2
volume to 10 Gy (to 100%)  in five daily fractions
during  the  sixth  week.  Where  considered  more
appropriate,  phase  2  was  treated  with  an  electron
field.  During  the  period  analysed,  a  number  of
patients were treated in a study of hyperfractionated
radiotherapy.16  The  planning  protocol  was
unchanged but the phase 1 volume received 60Gy in
50 fractions of 1.2 Gy given twice daily over 5 weeks.
The phase 2 volume then received a further 12 Gy in
10 twice daily fractions during the sixth week of treat-
ment.
In each case of local recurrence we retrospectively
reviewed diagnostic imaging, planning radiographs,
portal films, prescription sheet diagrams and dosime-
try details. We analysed firstly whether placement of
the volumes had been appropriate and secondly the
relationship between site of recurrence to the phase 1
and 2 volumes. Planning films were not available for
three patients, but the relationship between the radi-
ation field and origin of recurrence (phase 1, phase 2
or out of field) was deduced using the case notes and
prescription sheet. In six cases the geographical origin
of the recurrence was difficult to identify due to the
recurrence  being  extensive  or  marginal  (on  the
margin of one of the volumes). In five cases there was
an obvious epicentre and the site of the recurrence
was allocated accordingly. The remaining case was
truly marginal. Portal images were present for most
patients and in all cases lead protection to normal
tissue had been positioned as prescribed.
Results
Analysis of recurrence (Table 4)
The commonest soft tissue sarcoma types seen were
(in decreasing order of frequency): leiomyosarcoma,
malignant  fibrous  histiocytoma,  liposarcoma  and
synovial sarcoma. Numbers are too small to permit
formal statistical analysis of variations in recurrence
rate according to histological subtype.
The  median  time  to  local  recurrence  was  21
months  (range  3–86  months)  with  eight  (32%)
occurring within  1  year  and eight at  or beyond  3
years. Two patients did not receive a radical dose.
One had received 33 Gy at another hospital prior to
surgery and received a further 40 Gy under our care,
subsequently  demonstrating  recurrence  on  the
margin  of  the  phase  1  radiation  field.  The  other
patient (with an obturator internus leiomyosarcoma)
stopped  treatment  at  46  Gy  because  of  suspected
intra-abdominal progression; no disease was found at
laparotomy but an  in-field recurrence occurred 22
months later. The remaining 23 patients received at
least 60 Gy and have been divided into those with
positive and those with negative pathological  mar-
gins. A total of eight patients who received radical
dose had positive margins or were thought to have a
high risk of residual microscopic disease due to sub-
optimal surgery such as enucleation. An out-of-field
relapse occurred in one patient who had undergone
multiple  excisions,  laser  vapourisations  and  skin
grafting  before radiotherapy;  the  radiation  volume
did  not  encompass  all  the  previously  grafted  area
because of concern regarding morbidity. The seven
remaining  patients  received  radiotherapy  strictly
according to protocol: six recurred in the phase 2 and
one in the phase 1 volume (treated with hyperfrac-
tionation).  One  of  the  phase  2  recurrences  had
undergone enucleation only with further excision not
having been undertaken due to complications associ-
ated with the initial surgery. Therefore, in this patient
surgery had  been suboptimal, but  in the  other six
there were no identified technical causes for treat-
ment failure.
There were 15 patients with clear histological mar-
gins who relapsed despite radical dose radiotherapy.
One patient with liposarcoma of chest wall received
Table 3. Treatment details
Case
Phase 1:
Dose(Gy)/Number of 
fractions/frequency/
beam
Phase 2:
Dose(Gy)/Number of 
fractions/frequency/
beam
1 40/20/daily/photons Not given
2 46/23/daily/photons Not given
3 60/50/bd/photons 12/10/bd/photons
4 52.5/25/daily/photons 7.5/5/daily/photons
5 50/25/daily/photons 10/5/daily/photons
6 50/25/daily/photons 10/5/daily/photons
7 60/50/bd/photons 12/10/bd/photons
8 50/25/daily/photons 12.5/5/daily/electrons
9 50/25/daily/photons 12.5/5/daily/electrons
10 50/25/daily/electrons 10/5/daily/electrons
11 47/23/daily/photons 13/5/daily/electrons
12 50/25/daily/photons 10/5/daily/photons
13 50/25/daily/photons 10/5/daily/photons
14 60/50/bd/photons 12Gy/10/bd/photons
15 60/50/bd/photons 12Gy/10/bd/photons
16 50/25/daily/photons 10Gy/5/daily/photons
17 40/20/daily/photons 20Gy/10/daily/photons
18 50/25/daily/photons 10Gy/5/daily/photons
19 60/50/bd/photons 12Gy/10/bd/photons
20 50/25/daily/photons 10Gy/5/daily/photons
21 50/25/daily/photons 10Gy/5/daily/photons
22 50/25/daily/photons 10Gy/5/daily/photons
23 50/25/daily/photons 10Gy/5/daily/photons
24 60/50/bd/photons 12Gy/10/bd/photons
25 50/25/daily/photons 10Gy/5/daily/photons86 Cleator et al.
only 47 Gy to the phase 1 volume and relapsed within
this volume. Another patient who was treated for a
pleomorphic liposarcoma of the left triceps relapsed
locally outside the volume; this treatment could be
criticised  for  not  having  covered  adequately  the
muscle origin. One patient relapsed following treat-
ment  for  a  grade  2  fibrosarcoma  arising from  the
lower end of the psoas muscle; the radiation field did
not cover the upper part of the pelvis due to risk of
bowel toxicity; recurrence occurred above the proxi-
mal field margin. The remaining 12 cases conformed
strictly to our protocol: 11 recurred in the phase 2
volume (four hyperfractionated) and one within the
phase 1 volume.
Patient outcome
With a median follow-up time since completing radi-
otherapy of 58 months, 10 patients have died. Nine
deaths were disease-related and all died with meta-
static disease. At time of writing, eight of the 15 sur-
vivors are alive and disease-free, although three have
undergone pulmonary metastasectomy and four have
required limb or, in one case, finger amputation. One
patient has been lost to follow-up. Five survive with
persistent local disease and one with metastatic dis-
ease.
Discussion
The ultimate aim in the management of soft tissue
sarcoma is to achieve local control and cure whilst
ensuring organ preservation and limb function. The
value  of  radiotherapy  in reducing the incidence of
local recurrence following conservative surgery has
been demonstrated in historical series1 and in two
prospective randomised trials.12,17 Debate continues
in the literature as to whether improved local control
translates to improved survival.7,12 In retrospective
studies local recurrence has been associated with a
poorer survival. However, this may not be a causal
relationship  but  rather  an  association  that  arises
because  locally  recurrent  tumours  are  biologically
more aggressive.
Tumour-related  factors  shown  to  be  associated
with risk of local recurrence include high-grade his-
tology,4,8,12 size greater than 5 cm in diameter2,8 and
previous  local  recurrence.3  In  Pister’s  analysis  of
1041 patients with extremity soft tissue sarcoma his-
tological  subtypes  fibrosarcoma  and  malignant
peripheral nerve tumour were significant independ-
ent adverse prognostic factors for local recurrence.18
With regard to treatment, presence of histologically
positive margins, radiotherapy dose and radiotherapy
margins have been analysed as possible factors influ-
encing local control. Several retrospective series sup-
port the significance of positive operative margins in
this respect.5,6,8,18 Mundt7 retrospectively reviewed
64 cases of soft tissue sarcoma treated by conservative
surgery and adjuvant radiotherapy. Patients treated
with an initial field margin beyond the tumour of <5
cm had a 5-year local control rate significantly worse
than those treated with an initial field margin of >5
cm  (30  vs.  93%,  p  =  0.0003).  Fein6  reviewed 67
patients  (again  retrospectively),  and  demonstrated
significantly improved local control associated with a
Table 4. Detail of relapse
Case Margin status Site of relapse
Treatment factors possibly 
contributing to local relapse
1 Clear Margin of phase 1 Sub-optimal dose 
2 Positive Within phase 1 Sub-optimal dose
3 Positive Out of field Whole of grafted area not covered 
4 Positive Within phase 2 None
5 Positive Within phase 2 (extensive) None
6 Positive Within phase 2 Sub-optimal surgery (enucleation)
7 Positive  Within phase 1 None
8 Positive Within phase 2 None
9 Positive Within phase 2 None
10 Positive Within phase 2 None
11 Clear Within phase 1 Phase 1 dose sub-optimal
12 Clear Within phase 1 (extensive) None
13 Clear Out of field (extensive) Muscle origin not covered
14 Clear Within phase 2 None
15 Clear Within phase 2 None
16 Clear Out of field Muscle origin not covered 
18 Clear Within phase 2 (extensive) None
19 Clear Within phase 2 (extensive) None
20 Clear Within phase 2 None
21 Clear Within phase 2 None
22 Clear Within phase 2 None
23 Clear Within phase 2 None
24 Clear Within phase 2 None
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dose of ‡ 62.5 Gy compared with <62.5 Gy (95 vs.
78%). It is too early to assess the benefit of delivering
radiotherapy  in  a  hyperfractionated  manner,
although a phase 2 study in our centre demonstrated
the regimen to be well tolerated with local control
comparable to standard fractionation.16
Can analysis of our data tell us anything about the
importance of margin status, the adequacy in size of
the phase 1/2 volumes and the dose received to each?
In  six  patients  technical  factors  can  be  identified
which may have accounted for failure, including all
three out of field recurrences.
Eleven patients recurred inside the phase 2 volume
despite  negative  margins,  of  whom  four  had  been
treated with the hyperfractionated regimen. Assuming
an a /b  ratio of 10 for tumour, this hyperfractionated
regimen delivers an 11% increase in effective dose for
tumour control relative  to  standard treatment.16  A
radiation dose-response for  sarcoma cells has  been
demonstrated  in  experimental  systems,19  although
prospective, randomised clinical data are lacking. Our
adjuvant dose of 60 Gy is less than that applied in
many centres where doses approach 70 Gy. It is pos-
sible that some of our local recurrences may have been
avoided by delivery of a higher dose. Furthermore,
work is required to determine if different doses should
be applied to different sub-classes of sarcoma. In our
centre treatment has always been given in two phases,
the rationale being that the phase 2 volume requires a
higher dose and because of concerns regarding the
toxicity associated with the delivery of a full radical
dose to a large phase 1 volume. However, any clono-
genic  cells  remaining  after  surgery  in  the  phase  1
volume will have inherent radiobiological properties
identical to those remaining in the phase 2 volume,
although there may be differences in the number of
clonogenic cells and the tumour microenvironment,
particularly  oxygenation.  A  single-phase  approach
may be acceptable, particularly if more limited radia-
tion field sizes are to be adopted.
Furthermore,  it  is  conceivable  that  subsequent
local relapse may have been prevented in margin pos-
itive cases by further surgery (where technically feasi-
ble) to achieve microscopically negative margins.
Treatment in six patients deviated from our radio-
therapy protocol for reasons defined above. Of the 19
patients  treated  strictly according to protocol, two
relapsed in the phase 1 volume and 17 in the phase 2
volume. Therefore, the majority of patients relapse at
or very close to the tumour bed. On the basis of the
results of this study it is possible to suggest that either
treatment may be delivered as effectively with a ‘lim-
ited field’ or that 50 Gy is effective in treating micro-
scopic disease within the phase 1 volume. Indeed the
Memorial  Sloan-  Kettering  group12  achieved  very
good local control rates by irradiating the tumour bed
with a margin of 2 cm only by means of brachyther-
apy supporting the former of these conclusions. The
rationale  of  extending the  irradiated  volume  from
muscle  origin  to  insertion  is  the  phenomenon  of
tumour foci extending far beyond the pseudocapsule
of the tumour and the observation that fascial planes
act as natural barriers to spread.20 In reality the inci-
dence of distant satellite lesions is probably small.
Our study originated as an audit, undertaken to see
if changes could be made to reduce local recurrence.
However,  retrospective  assessment  of  the  gross
tumour  volume  (GTV),  planning  target  volume
(PTV) and relative site of recurrence proved difficult.
In particular it was difficult to assess the relationship
between GTV and PTV in three dimensions, even
when all the written and radiographic records were
available.
Whether treatment of the entire muscle compart-
ment is necessary has been called into question by
Mundt’s data7 which showed no benefit in treating
patients with an initial field margin of greater than 10
cm. To date there has been no prospective evaluation
of  the  radiotherapy  margins  in  the  post-operative
treatment of soft tissue sarcoma. Similarly, dose has
not been assessed in a prospective study. Whether
there is a sufficient number of patients for a success-
ful randomised trial is questionable, particularly in
view of the inconsistency in surgical management and
the variety of tumour-related factors.
An alternative would be to establish a means of
prospectively reporting all  cases treated with com-
bined  modality  treatment  in  which  would  be
recorded:
1. Status of the surgical margins.
2. GTV,  clinical  target  volume  (CTV)  and  PTV
described in  a  standardised  manner with  mini-
mum margins in three dimensions.
3. Dose delivered to the PTV expressed in accord-
ance with ICRU guidelines.
4. Standardised late radiation morbidity score.
5. Relationship of site of recurrence to the phase 1
and 2 PTV confirmed by re-simulation.
In the absence of an evidence base this would provide
a starting point towards a standard treatment policy
across centres, allowing for the  prospective assess-
ment of  field margins or  even a  randomised trial.
Given the evidence that late morbidity is related to
both the  volume irradiated and the  total  dose,8,11
there is clearly a need to optimise the dimensions of
the irradiated volume to achieve the best therapeutic
ratio. Furthermore, there are undoubtedly patients
who do not require post-operative radiotherapy.17 In
the future it may be possible to predict with more
accuracy those patients who will be controlled locally
by surgery alone and who therefore may be spared the
morbidity of radiotherapy.
Conclusions
The greatest challenge in reducing local recurrence of
high-grade sarcomas by adjuvant radiotherapy is the88 Cleator et al.
control of microscopic disease in the  tumour bed.
Irradiation of the entire muscle compartment may
not be necessary. However, caution should be exer-
cised when using a retrospective review of this kind to
recommend changes in treatment  policy. We have
highlighted the need for accurate recording of the site
and dimensions of the primary tumour and the radi-
otherapy parameters employed. If the precise rela-
tionship  between  site  of  recurrence and  irradiated
volume as well as treatment morbidity are prospec-
tively recorded, then it may be possible to define an
evidence based optimal treatment policy.
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